Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP731529.RAbBAkKkZ1Ky2W4k_8mnrewsoCngiTNZLThDUJVFmZwSQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP731529.RAbBAkKkZ1Ky2W4k_8mnrewsoCngiTNZLThDUJVFmZwSQ130_assertion type Assertion NP731529.RAbBAkKkZ1Ky2W4k_8mnrewsoCngiTNZLThDUJVFmZwSQ130_head.
- NP731529.RAbBAkKkZ1Ky2W4k_8mnrewsoCngiTNZLThDUJVFmZwSQ130_assertion description "[Preclinical data with SGLT2 inhibitors, such as dapagliflozin and sergliflozin, show that these compounds are highly selective inhibitors for SGLT2, have beneficial effects on the glucose utilization rate, and reduce hyperglycemia while having no hypoglycemic adverse effects.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP731529.RAbBAkKkZ1Ky2W4k_8mnrewsoCngiTNZLThDUJVFmZwSQ130_provenance.
- NP731529.RAbBAkKkZ1Ky2W4k_8mnrewsoCngiTNZLThDUJVFmZwSQ130_assertion evidence source_evidence_literature NP731529.RAbBAkKkZ1Ky2W4k_8mnrewsoCngiTNZLThDUJVFmZwSQ130_provenance.
- NP731529.RAbBAkKkZ1Ky2W4k_8mnrewsoCngiTNZLThDUJVFmZwSQ130_assertion SIO_000772 19357717 NP731529.RAbBAkKkZ1Ky2W4k_8mnrewsoCngiTNZLThDUJVFmZwSQ130_provenance.
- NP731529.RAbBAkKkZ1Ky2W4k_8mnrewsoCngiTNZLThDUJVFmZwSQ130_assertion wasDerivedFrom befree-2016 NP731529.RAbBAkKkZ1Ky2W4k_8mnrewsoCngiTNZLThDUJVFmZwSQ130_provenance.
- NP731529.RAbBAkKkZ1Ky2W4k_8mnrewsoCngiTNZLThDUJVFmZwSQ130_assertion wasGeneratedBy ECO_0000203 NP731529.RAbBAkKkZ1Ky2W4k_8mnrewsoCngiTNZLThDUJVFmZwSQ130_provenance.